Compare FOR & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FOR | TYRA |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2007 | 2021 |
| Metric | FOR | TYRA |
|---|---|---|
| Price | $30.31 | $27.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $31.75 | ★ $42.75 |
| AVG Volume (30 Days) | 197.6K | ★ 769.6K |
| Earning Date | 01-20-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.27 | N/A |
| Revenue | ★ $1,685,000,000.00 | N/A |
| Revenue This Year | $0.52 | N/A |
| Revenue Next Year | $7.72 | N/A |
| P/E Ratio | $9.27 | ★ N/A |
| Revenue Growth | ★ 15.89 | N/A |
| 52 Week Low | $18.00 | $6.42 |
| 52 Week High | $30.74 | $33.99 |
| Indicator | FOR | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 71.28 | 43.87 |
| Support Level | $29.13 | $24.88 |
| Resistance Level | $29.87 | $33.99 |
| Average True Range (ATR) | 0.95 | 2.57 |
| MACD | 0.32 | -0.53 |
| Stochastic Oscillator | 93.22 | 34.14 |
Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. the company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.